[The biomarkers of cerebral ischemia as a new method for the validation of the efficacy of cytoprotective therapy].

Autor:	Dambinova SA; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Aliev KT; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Bondarenko EV; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Ponomarev GV; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Skoromets AA; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Skoromets AP; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Skoromets TA; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Smolko DG; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Shumilina MV; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2017; Vol. 117 (5), pp. 62-67.
DOI:	10.17116/jnevro20171175162-67
Abstrakt:	Aim: To study blood plasma concentrations of NR2-peptide in patients with ischemic stroke (IS) to assess its diagnostic value as a biomarker of cerebral ischemia and determine the dynamics of the biomarker during treatment with cortexin. Material and Methods: One hundred and twenty patients, aged from 18 to 70 years, including 36 with transient ischemic attack (TIA) and 84 with IS in the carotid territory (n=70) and vertebral/basilar territory with the Wallenberg-Zakharchenko syndrome (n=14), were enrolled. The National Institute of Health Stroke scale (NIHSS) was used to assess neurological status. Blood plasma concentration of NR2-peptide was measured in all patients at admission and after treatment. All laboratory results were compared with neuroimaging (MRI, CT) data. Results: Concentrations of NR2-peptide detected in all patients were higher than in controls (>1.5 ng/ml), p<0.0001. The direct correlation between NR2-peptide (from 3.38 ng/ml to 15.6 ng/ml) and ischemic lesion (from few to 80 mm) was observed. A decrease in NR2-peptide concentration (from 8.5 to 5,.9 ng/ml, p<0.0001) was noted in patients treated with cortexin after 10-day treatment course. Conclusion: NR2-peptide blood assay is a reliable hemotest of brain ischemia. Cortexin has a sufficient therapeutic efficacy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu